u/kaia_cabrera

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.

Careful. "Nobody has tested Hunan GoodPeptides Biotech" is a statement about this board, not about the supplier. Say the first thing, not the second.

Do you have the publication or the press release?

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

Read a press release and the publication three months apart. The hedging in the second one was substantial.

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

Network fees are set by chain congestion at the time of sending. They are paid to the network, not to the recipient, and they vary by hour as well as by chain.

Have you held a step for longer than the four-week minimum at any point?

the four-week step schedule is the label, not folklore

2.5 is the starter dose and it is not meant to be the dose that works

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

The wider-market rows in the directory carry a band and a report count and nothing else, deliberately. Anything more would be manufacturing precision that the evidence does not support.

postprandial excursions are where most of the improvement shows up first

the second-level appeal is where things actually turn

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

what does the certificate actually carry — that is the whole question

That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.

Correcting myself: 18 weeks between those two A1c results, which is too short an interval to interpret.

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

research material is not approved for human use, which is why the clinical record here is thin

CGM shows you the shape, A1c shows you the area

stepping every four weeks is a ceiling on speed, not a schedule you must hit

step therapy is a documentation problem, not an argument

This. Ask for the batch record. The ones who send it inside a day have told you more than any review could.

Confirmations are the count of blocks built on top of the one containing your transaction. Until there are some, the transaction is not settled in any meaningful sense.

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

Are you comparing yourself with the trial mean or with the people who post the most?

bastian_eriksen is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

What step are you on and how long have you been there?

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

Adding the standing caveat — unapproved compound, research material is not for human use.

This is the framing the board needs. It is a hepatic programme first.

check the trial population before quoting a result at somebody

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

escrow arrangements are rare and worth asking about